Please use this identifier to cite or link to this item:
Title: Metformin and Breast Cancer: Where Are We Now?
Author: Cejuela, Mónica
Martin Castillo, Begoña
Menendez, Javier A.
Pernas, Sònia
Keywords: Càncer de mama
Breast cancer
Issue Date: 28-Feb-2022
Publisher: MDPI AG
Abstract: Breast cancer is the most prevalent cancer and the leading cause of cancer-related death among women worldwide. Type 2 diabetes-associated metabolic traits such as hyperglycemia, hyperinsulinemia, inflammation, oxidative stress, and obesity are well-known risk factors for breast cancer. The insulin sensitizer metformin, one of the most prescribed oral antidiabetic drugs, has been suggested to function as an antitumoral agent, based on epidemiological and retrospective clinical data as well as preclinical studies showing an antiproliferative effect in cultured breast cancer cells and animal models. These benefits provided a strong rationale to study the effects of metformin in routine clinical care of breast cancer patients. However, the initial enthusiasm was tempered after disappointing results in randomized controlled trials, particularly in the metastatic setting. Here, we revisit the current state of the art of metformin mechanisms of action, critically review past and current metformin-based clinical trials, and briefly discuss future perspectives on how to incorporate metformin into the oncologist's armamentarium for the prevention and treatment of breast cancer.
Note: Reproducció del document publicat a:
It is part of: International Journal of Molecular Sciences, 2022, vol. 23, num. 5
Related resource:
ISSN: 1422-0067
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
ijms-23-02705-v3.pdf1.5 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons